Raymond James Financial reissued their hold rating on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a report published on Monday morning.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research raised ZIOPHARM Oncology from a hold rating to a buy rating and set a $5.25 price target for the company in a report on Friday, November 10th. HC Wainwright reissued a buy rating and set a $9.50 target price on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. ValuEngine raised ZIOPHARM Oncology from a sell rating to a hold rating in a report on Monday, August 28th. Finally, BidaskClub downgraded ZIOPHARM Oncology from a hold rating to a sell rating in a report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $12.75.

Shares of ZIOPHARM Oncology (ZIOP) opened at $4.26 on Monday. ZIOPHARM Oncology has a twelve month low of $3.90 and a twelve month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. During the same period in the prior year, the business earned ($0.11) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts forecast that ZIOPHARM Oncology will post -0.54 EPS for the current year.

In other news, CEO Laurence James Neil Cooper bought 6,440 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $4.68 per share, with a total value of $30,139.20. Following the completion of the acquisition, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 10.40% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of ZIOP. Teachers Advisors LLC raised its stake in ZIOPHARM Oncology by 8.3% in the first quarter. Teachers Advisors LLC now owns 214,906 shares of the biotechnology company’s stock valued at $1,363,000 after purchasing an additional 16,398 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in ZIOPHARM Oncology by 5.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 538,289 shares of the biotechnology company’s stock valued at $3,413,000 after purchasing an additional 27,906 shares in the last quarter. Credit Suisse AG raised its stake in ZIOPHARM Oncology by 27.7% in the first quarter. Credit Suisse AG now owns 182,699 shares of the biotechnology company’s stock valued at $1,158,000 after purchasing an additional 39,597 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in ZIOPHARM Oncology in the second quarter valued at about $1,010,000. Finally, National Planning Corp raised its stake in ZIOPHARM Oncology by 6.3% in the second quarter. National Planning Corp now owns 33,755 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 2,000 shares in the last quarter. 40.25% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “ZIOPHARM Oncology (ZIOP) Rating Reiterated by Raymond James Financial” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/ziopharm-oncology-ziop-rating-reiterated-by-raymond-james-financial/1765382.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with Analyst Ratings Network's FREE daily email newsletter.